1st Annual Regen Med Investor Day

Platform to Bedside

Marc Hedrick, MD

President

Safe Harbor Statement

This presentation contains certain ‘forward-looking statements’ about Cytori Therapeutics, Inc. All

statements, other than statements of historical fact, that address activities, events or developments that we

intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements.

Such statements are based upon certain assumptions and assessments made by our management in light of

their experience and their perception of historical trends, current conditions, expected future developments

and other factors they believe to be appropriate.

The forward-looking statements included in this presentation involve known and unknown risks that relate to

Cytori’s future events or future financial performance and the actual results could differ materially from those

discussed in this presentation. Risks and uncertainties that may cause Cytori's actual results to differ

materially from those discussed in the presentation can be found in the "Risk Factors" section of Cytori’s

Form 10-K, Forms 10-Q and other filings with the United States Securities and Exchange Commission. We

would advise reading our most recent annual report on Form 10-K and quarterly report on Form 10-Q filed

with the United States Securities and Exchange Commission for a more detailed description of these risks.

The forward-looking statements contained in this presentation represent Cytori’s estimates and assumptions

only as of the date of this presentation and Cytori undertakes no duty or obligation to update or revise

publicly any forward-looking statements contained in this presentation as a result of new information, future

events or changes in Cytori’s expectations.

Cytori Platform: Technology

Technology for cell

isolation, combination

with other factors,

storage and clinical

therapy

STEP 1 Harvest patient

tissue (100cc)

STEP 2 Separate &

Process

STEP 3 Deliver ADRCs to

Same Patient, ~1 hr.

Cytori Platform: Model

Goal: Leadership in Regenerative Medicine

Research &

Development

Basic

Science

Product

Development

CAPITAL

Regulatory

Approval

Device Approvals

Therapeutic

Approvals

Clinical

Use

Safety

Efficacy

Commercial

Self Pay

Reimbursement

PROFIT

Cytori Platform: Case Study

Gen One

Device

EU

Approval

EU

Breast

Pivotal

Japan

Breast

Pilot

Radiation

Injury, BARDA

Ischemia &

CV Trials

Sales

Other Approvals

& Applications

Cytori Cell Therapy:

US Government Contract

Discussions

Begin

2010

Award

Announcement

Fall, 2012

3 Objectives Trigger

Option 1 & 3

Q1, 2014

3 Proof-of-concept Objectives

Ongoing

Cell viability

Animal model POC

Next Gen device feasibility

$32.6 M Option 1

$23.4M Option 3

Commercial Acquisition at

BARDA’s Discretion

$45.5M Option 2

Option 1 Objective

Triggers Option 2

Q4, 2015

Pre-Award, White Papers,

Proposal, Negotiation

$4.7M Phase 1 Proof of Concept

Cytori Platform: Clinical Trials and Studies

43 total: 2 Cytori sponsored trials & 41 investigator studies

USA

1 EU

23 AP

13

EM

6

Soft Tissue: 18

Wound: 7

Ischemia: 2

Ortho/Sport: 8

Vital Organ: 8

Total: 43